Generic Idhifa Availability
Last updated on Apr 10, 2025.
Idhifa is a brand name of enasidenib, approved by the FDA in the following formulation(s):
IDHIFA (enasidenib mesylate - tablet;oral)
-
Manufacturer: BRISTOL MYERS SQUIBB
Approval date: August 1, 2017
Strength(s): EQ 50MG BASE [RLD], EQ 100MG BASE [RLD]
Is there a generic version of Idhifa available?
No. There is currently no therapeutically equivalent version of Idhifa available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Idhifa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Therapeutically active compounds and their methods of use
Patent 10,093,654
Issued: October 9, 2018
Inventor(s): Agresta Samuel V. & Gu Chong-Hui & Schenkein David & Yang Hua & Guo Liting & Tang Zhen & Wang Jianming & Zhang Yanfeng & Zhou Yan
Assignee(s): Agios Pharmaceuticals, Inc.Provided are compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein.
Patent expiration dates:
- August 1, 2034✓✓✓
- August 1, 2034
-
Therapeutically active compounds and their methods of use
Patent 10,294,215
Issued: May 21, 2019
Inventor(s): Cianchetta Giovanni & DeLaBarre Byron & Popovici-Muller Janeta & Salituro Francesco G. & Saunders Jeffrey O. & Travins Jeremy & Yan Shunqi & Guo Tao & Zhang Li
Assignee(s): Agios Pharmaceuticals, Inc.Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Patent expiration dates:
- January 7, 2033✓✓
- January 7, 2033
-
Methods and compositions for cell-proliferation-related disorders
Patent 10,610,125
Issued: April 7, 2020
Inventor(s): Dang Lenny & Fantin Valeria & Gross Stefan & Jang Hyun Gyung & Jin Shengfang & Salituro Francesco G. & Saunders Jeffrey O. & Su Shin-San Michael & Yen Katharine
Assignee(s): Agios Pharmaceuticals, Inc.Methods of treating and evaluating subjects having neoactive mutants are described herein.
Patent expiration dates:
- June 21, 2030✓
- June 21, 2030
-
Therapeutically active compositions and their methods of use
Patent 9,512,107
Issued: December 6, 2016
Inventor(s): Cianchetta Giovanni & DeLaBarre Byron & Popovici-Muller Janeta & Salituro Francesco G. & Saunders Jeffrey O. & Travins Jeremy & Yan Shunqi & Guo Tao & Zhang Li
Assignee(s): Agios Pharmaceuticals, Inc.Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Patent expiration dates:
- January 7, 2033✓✓✓
- January 7, 2033
-
Therapeutically active compounds and their methods of use
Patent 9,732,062
Issued: August 15, 2017
Inventor(s): Cianchetta Giovanni & DeLaBarre Byron & Popovici-Muller Janeta & Salituro Francesco G. & Saunders Jeffrey O. & Travins Jeremy & Yan Shunqi & Guo Tao & Zhang Li
Assignee(s): Agios Pharmaceuticals, Inc.Provided are compounds useful for treating cancer and methods of treating cancer comprising administering to a subject in need thereof a compound described herein.
Patent expiration dates:
- September 16, 2034✓
- September 16, 2034
-
Therapeutically active compounds and their methods of use
Patent 9,738,625
Issued: August 22, 2017
Inventor(s): Agresta Samuel V. & Gu Chong-Hui & Schenkein David & Yang Hua & Guo Liting & Tang Zhen & Wang Jianming & Zhang Yanfeng & Zhou Yan
Assignee(s): Agios Pharmaceuticals, Inc.Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes.
Patent expiration dates:
- August 1, 2034✓
- August 1, 2034
More about Idhifa (enasidenib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.